RxDoctor Payments Data

Jose Cantu, MD

Pulmonary Disease · Texas City, TXNPI 1366627523

Payments from drug & device makers

$42,420in general payments, 2019–2025

Across 1,069 payments — averaging $39.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Specialty L.p.$14K
  • Insmed, Inc.$10K
  • AstraZeneca$4K
  • GSK$3K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Boehringer Ingelheim$1K
  • plus $9K from 36 others

What the payments were for

  • Consulting fees$2,4346%
  • Speaking & faculty fees$16,32138%
  • Travel & lodging$1,7134%
  • Food & beverage$21,60251%
  • Education$3511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,420 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$323,947
Medicare patients
657
Services billed
3,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter557$469,956
OfevNintedanib Esylate14$183,032
Breztri AerosphereBudesonide/Glycopyr/Formoterol162$128,494
NucalaMepolizumab20$73,756
Dupixent SyringeDupilumab12$49,657
Breo ElliptaFluticasone/Vilanterol93$40,874
Stiolto RespimatTiotropium Br/Olodaterol Hcl58$31,206
Spiriva RespimatTiotropium Bromide44$30,231
EliquisApixaban25$20,844
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr41$20,372
Atrovent HfaIpratropium Bromide22$17,797
SymbicortBudesonide/Formoterol Fumarate33$13,325
Albuterol Sulfate HfaAlbuterol Sulfate432$12,590
Varenicline Tartrate31$10,394
Combivent RespimatIpratropium/Albuterol Sulfate15$9,765

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta$2,971$604,957711 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$1,249$254,233131 claims
AstraZenecaBreztri Aerosphere, Symbicort$3,906$141,818195 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Texas City

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →